Suppr超能文献

通过患者来源的异种移植模型实现非小细胞肺癌个体化治疗:考虑的临床前和临床因素。

Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.

机构信息

The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Institute of Pathology, Soroka University Medical Center, Beer-Sheva, Israel.

出版信息

Clin Transl Oncol. 2024 Sep;26(9):2227-2239. doi: 10.1007/s12094-024-03450-3. Epub 2024 Mar 29.

Abstract

PURPOSE

In the pursuit of creating personalized and more effective treatment strategies for lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as preclinical platforms that can recapitulate the specific patient's tumor in an in vivo model. We investigated how well PDX models can preserve the tumor's clinical and molecular characteristics across different generations.

METHODS

A Non-Small Cell Lung Cancer (NSCLC) PDX model was established in NSG-SGM3 mice and clinical and preclinical factors were assessed throughout subsequent passages. Our cohort consisted of 40 NSCLC patients, which were used to create 20 patient-specific PDX models in NSG-SGM3 mice. Histopathological staining and Whole Exome Sequencing (WES) analysis were preformed to understand tumor heterogeneity throughout serial passages.

RESULTS

The main factors that contributed to the growth of the engrafted PDX in mice were a higher grade or stage of disease, in contrast to the long duration of chemotherapy treatment, which was negatively correlated with PDX propagation. Successful PDX growth was also linked to poorer prognosis and overall survival, while growth pattern variability was affected by the tumor aggressiveness, primarily affecting the first passage. Pathology analysis showed preservation of the histological type and grade; however, WES analysis revealed genomic instability in advanced passages, leading to the inconsistencies in clinically relevant alterations between the PDXs and biopsies.

CONCLUSIONS

Our study highlights the impact of multiple clinical and preclinical factors on the engraftment success, growth kinetics, and tumor stability of patient-specific NSCLC PDXs, and underscores the importance of considering these factors when guiding and evaluating prolonged personalized treatment studies for NSCLC patients in these models, as well as signaling the imperative for additional investigations to determine the full clinical potential of this technique.

摘要

目的

为了为肺癌患者制定个性化且更有效的治疗策略,人们引入了患者来源异种移植(PDX)作为能够在体内模型中重现特定患者肿瘤的临床前平台。我们研究了 PDX 模型在多大程度上能够在不同代际中保留肿瘤的临床和分子特征。

方法

在 NSG-SGM3 小鼠中建立非小细胞肺癌(NSCLC)PDX 模型,并在随后的传代过程中评估临床和临床前因素。我们的队列包括 40 名 NSCLC 患者,他们被用于在 NSG-SGM3 小鼠中创建 20 个患者特异性 PDX 模型。进行组织病理学染色和全外显子组测序(WES)分析,以了解整个连续传代过程中的肿瘤异质性。

结果

促成移植 PDX 在小鼠中生长的主要因素是疾病的较高分级或分期,而不是化疗治疗的较长持续时间,这与 PDX 繁殖呈负相关。成功的 PDX 生长也与较差的预后和总生存期相关,而生长模式的可变性受肿瘤侵袭性的影响,主要影响第一代。病理学分析显示保留了组织学类型和分级;然而,WES 分析显示在高级别中存在基因组不稳定性,导致 PDX 和活检之间在临床上相关改变方面存在不一致。

结论

我们的研究强调了多种临床和临床前因素对特定于患者的 NSCLC PDX 移植成功率、生长动力学和肿瘤稳定性的影响,并强调了在这些模型中指导和评估 NSCLC 患者延长的个性化治疗研究时考虑这些因素的重要性,同时也表明需要进一步研究以确定该技术的全部临床潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e99/11333550/7b2a04bb3372/12094_2024_3450_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验